Immunic, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses), averaging -12.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.24 | $-0.80 | +35.5% | Beat | |
| Q1 FY26 | $-0.71 | $-1.08 | -52.1% | Miss | Q1 FY26 call |
| Q4 FY25 | $-0.10 | $-0.12 | -20.0% | Miss |
Back to IMUX overview · IMUX holders · IMUX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.